VTU and Biomay sign recombinant allergen licensing agreement

Two leading Austrian biotech companies, VTU Technology and Biomay, have entered into a licensing agreement for the production of recombinant allergens.

VTU Technology has granted Biomay access to VTU’s Pichia pastoria protein expression technology. Biomay will apply industrial Pichia expression strains generated by VTU for the commercial production of recombinant allergens. Under the terms of the agreement, VTU will receive royalties based on Biomay’s worldwide sales of the recombinant allergens.

The Pichia platform enables the production of high-performance strains, high-quality proteins, and economically viable production processes.